// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Sputum Interleukin 5 in eosinophilic and non-eosinophilic severe asthma

Adnan Azim - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Interleukin

Dupilumab efficacy in patients with GINA-defined type 2 asthma: TRAVERSE

Eric D. Bateman - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Dupilumab

Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial

Robyn Kendall - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

fluticasone furoate/umeclidinium/vilanterol

Correlation between histological yield of intrathoracic nodal EBUS biopsy and SUVmax in 18F-FDG PET scan

Samiha Naureen - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Fludeoxyglucose (18F)

Estimation of the Alveolar Partial Pressure of Oxygen using Hyperpolarized Helium-3: The Multi-Ethnic Study of Atherosclerosis (MESA) COPD Study

Naz P. Taskiran - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Coronary Artery Disease

Helium

Economic burden associated with clinical management of COVID-19 – A literature review

Ember Lu - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Enhanced immune activation pathways enriched in patients =70 years with severe COVID-19

Luke O'Neill - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Otilimab

A respiratory department’s use of high-flow nasal oxygen and associated patient outcomes (prior to the COVID-19 pandemic)

Bharat Sharma - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

An appraisal of respiratory system compliance in mechanically ventilated COVID-19 patients

Gianluigi Li Bassi - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Potential for personalised application of inhaled nitric oxide in Covid-19 pneumonia

Benjamin Garfield - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Severe COVID-19 pneumonia

INO

Hospitalized patients aged =70 years were disproportionately affected by COVID-19

J. Morel Symons - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Dysphagia in patients with severe COVID-19 post extubation: Experience from a UK tertiary cardiothoracic centre

Lydia Spurr - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Predictors of weaning success in patients requiring prolonged invasive mechanical ventilation

Neeraj Shah - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Importance of admission biomarkers in prognostication of patients with SARS-Cov-2

Milan Barik - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Characterisation of COVID-19 hospitalised frail patients not for ICU admission

Yasser Noeman Ahmed - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Tracheostomy Practice and Outcomes in Patients with COVID–19 ARDS – insights from PRoVENT–COVID

Anissa Tsonas - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Could a 2-year mortality prediction model have prevented deaths from respiratory failure: a single UK centre experience

Kavita Dave - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Generating senescent airway epithelial cell populations using low-concentration doxorubicin or etoposide

Shyreen Hassibi - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Doxorubicin

Mycobacterium tuberculosis modulates mitochondrial function in human macrophages

Claudio Bussi - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

2-Deoxy-D-Glucose

Image analysis of tissue macrophages to confirm differential phagocytosis between groups by microscopy and automated bacterial quantification

Riccardo Wysoczanski - European Respiratory Society (ERS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

Copyright © 2026. QuantiNova All rights reserved